Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection
Journal Title: Viral Hepatitis Journal - Year 2020, Vol 26, Issue 2
Abstract
Objectives: This study aimed to investigate the effect of treatment with direct-acting antivirals (DAAs) on the virological response and on the some parameters used to evaluate liver function in cases with chronic liver disease due to hepatitis C virus (HCV) genotype 1b. Materials and Methods:This study included cases who were treated with DAAs after HCV genotype 1b infection. HCV-RNA levels and biochemical and hematological parameters measured at the beginning of treatment, 12th week and 52th week after the treatment were transferred to the SPSS statistics software. model for end-stage liver disease (MELD) and Child-Pugh scores were also calculated and added to these data. Results: The study group consisted of a total of 102 patients, including 33 (32%) males and 69 (68%) females. Compensated cirrhosis was detected in 26.5% of the patients (n=27). There was a significant change in serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and alpha-fetoprotein (AFP) parameters in patients with compensated cirrhosis after treatment, and total bilirubin, hemoglobin, ALT, AST, GGT, ALP and AFP parameters in the group without cirrhosis (p<0.05). Only a significant decrease was observed in the MELD score of the patients with compensated cirrhosis (p=0.007). Conclusion: The ombitasvir/paritaprevir/ritonavir+dasabuvir and ledipasvir/sofosbuvir regimens are very effective and safe in the treatment of patients who develop chronic liver disease and compensated liver cirrhosis after HCV genotype 1b infection.
Authors and Affiliations
Mustafa Doğan, Birol Topçu, Rıtvan Karaali, İlknur Erdem
Keywords
Related Articles
- EP ID EP688797
- DOI 10.4274/vhd.galenos.2020.2020.0016
- Views 116
- Downloads 0
Age Specific Hepatitis B Surface Antigen (HBsAg) and Anti-HBs Seroprevalence among Patients Admitted to a State Hospital
Objectives: Chronic hepatitis B (CHB) infection affects 257 million people globally, Turkey is middle endemic region. According to public health data, about 2 million people in Turkey are considered to be positive for he...
How Aware are We of the Immune Status of Hepatitis B and Hepatitis A in Chronic Hepatitis C Patients? A Multicenter Retrospective Study from Turkey
Objectives: Patients with chronic hepatitis C virus (HCV) infection and superinfection by hepatitis A or hepatitis B virus have higher morbidity and mortality when compared with those without HCV infection. The aim of th...
Frequency of HBV, HCV and HIV Infections and Determination of HCV Genotype Distribution in People who Inject Drugs
Objectives: The aim of this study was to determine the frequency of blood-borne infections [hepatitis B virus (HBV), HCV, and human immunodeficiency virus (HIV)] and the genotype distribution retrospectively in people wh...
The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients. Material...
Evaluation of Treatment Results with Direct Acting Antiviral Drugs of Cirrhotic/Non-cirrhotic Chronic Liver Disease Caused by Hepatitis C Virus Genotype 1b Infection
Objectives: This study aimed to investigate the effect of treatment with direct-acting antivirals (DAAs) on the virological response and on the some parameters used to evaluate liver function in cases with chronic liver...